Fragmented Trading in US Niche Stocks Driven by AI and Diagnostic CatalystsGlobal Report·13 hours agoVCYT-2.19%YJ-6.99%
Veradermics, Incorporated (MANE) Receives a Buy from LifeSci CapitalTip Ranks·Jul 18 at 04:05 PMMANE-5.48%
Weekly Buzz: NVS, MRK Win FDA Nod; LLY Snaps Up ATAI; MANE Shines On Hair Loss Datarttnews·Jul 18 at 12:22 AMCELC-6.47%MRK+0.45%
U.S. stock market midday update: VeraDermics up 8.39%, oral hair loss medication clinical benefits boost stock pricePrice Alert·Jul 17 at 12:38 PMMANE-5.48%
Veradermics to present age-subgroup data from VDPHL01 male hair loss trial at AAD Innovation AcademyPUBT·Jul 17 at 06:30 AMMANE-5.48%
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy | MANE Stock NewsStockTitan·Jul 16 at 10:30 PMMANE-5.48%
Veradermics, Incorporated (MANE) Gets a Buy from JefferiesTip Ranks·Jul 16 at 09:15 AMMANE-5.48%RANK-1.30%
Top Biotech Gainers: APLM Climbs 22%; IOVA, RCEL On Watch; MANE Gains On Hair Loss Datarttnews·Jul 15 at 10:42 PMIOVA-2.73%MANE-5.48%
Veradermics shares are trading higher after the company released topline results from an open-label Phase 2 trial evaluating its experimental VDPHL01 in women with mild-to-moderate pattern hair loss. Also, Needham maintained its Buy rating on the stock and raised its price target from $136 to $164.benzinga_article·Jul 15 at 12:49 PMMANE-5.48%
Needham & Company LLC Issues Positive Forecast for Veradermics (NYSE:MANE) Stock PriceMarket Beat·Jul 15 at 12:18 PMMANE-5.48%
Veradermics, Incorporated (MANE) Gets a Buy from LifeSci CapitalTip Ranks·Jul 15 at 09:35 AMMANE-5.48%
MANE: VDPHL01 showed rapid, robust hair regrowth and high patient satisfaction in women with pattern hair lossQuartr·Jul 15 at 09:26 AMMANE-5.48%
Veradermics Hair Loss Pill Shows Strong Phase II Signal in WomenMarket Beat·Jul 15 at 09:04 AMMANE-5.48%
